Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1915 4
1948 1
1951 1
1953 2
1954 1
1955 2
1956 6
1957 3
1958 3
1961 10
1962 21
1963 34
1964 27
1965 36
1966 39
1967 65
1968 56
1969 48
1970 58
1971 70
1972 25
1973 27
1974 45
1975 43
1976 38
1977 66
1978 47
1979 57
1980 58
1981 74
1982 73
1983 69
1984 81
1985 114
1986 98
1987 110
1988 105
1989 108
1990 111
1991 94
1992 104
1993 119
1994 124
1995 125
1996 173
1997 155
1998 195
1999 225
2000 228
2001 237
2002 263
2003 247
2004 291
2005 327
2006 338
2007 311
2008 302
2009 314
2010 310
2011 371
2012 437
2013 441
2014 466
2015 478
2016 498
2017 491
2018 493
2019 530
2020 624
2021 720
2022 768
2023 114
Text availability
Article attribute
Article type
Publication date

Search Results

11,638 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. Among authors: kato t. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: kato t. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Foxf2 represses bone formation via Wnt2b/β-catenin signaling.
Tanaka T, Takahashi A, Kobayashi Y, Saito M, Xiaolong S, Jingquan C, Ito Y, Kato T, Ochi H, Sato S, Yoshii T, Okawa A, Carlsson P, Inose H. Tanaka T, et al. Among authors: kato t. Exp Mol Med. 2022 Jun;54(6):753-764. doi: 10.1038/s12276-022-00779-z. Epub 2022 Jun 6. Exp Mol Med. 2022. PMID: 35668101 Free PMC article.
Tomoaki Kato, MD, MBA, FACS, The Marathon Surgeon.
Kato T. Kato T. Transplantation. 2022 Nov 1;106(11):2101-2103. doi: 10.1097/TP.0000000000004249. Epub 2022 Oct 21. Transplantation. 2022. PMID: 36279557 No abstract available.
From Basic Radiobiology to Translational Radiotherapy.
Chailapakul P, Kato TA. Chailapakul P, et al. Among authors: kato ta. Int J Mol Sci. 2022 Dec 14;23(24):15902. doi: 10.3390/ijms232415902. Int J Mol Sci. 2022. PMID: 36555542 Free PMC article.
Versatile Utilities of Amphibians (part 1).
Michiue T, Zorn AM, Kato T, Ochi H, Hayashi T, Inoue T. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Aug;64(6):264-265. doi: 10.1111/dgd.12805. Dev Growth Differ. 2022. PMID: 36088539 No abstract available.
Versatile utilities of amphibians (Part 3).
Michiue T, Kato T, Ochi H, Zorn A, Hayashi T, Inoue T, Kondo M, Taira M. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Dec;64(9):472-473. doi: 10.1111/dgd.12829. Dev Growth Differ. 2022. PMID: 36579413 No abstract available.
Versatile utilities of amphibians (part 2).
Michiue T, Zorn AM, Kato T, Ochi H, Hayashi T, Inoue T. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Sep;64(7):346. doi: 10.1111/dgd.12810. Dev Growth Differ. 2022. PMID: 36173152 No abstract available.
Editorial: The development of biomarkers in psychiatry.
Nakano T, Takamura M, Kato TA, Kano SI. Nakano T, et al. Among authors: kato ta. Front Psychiatry. 2022 Dec 1;13:1075993. doi: 10.3389/fpsyt.2022.1075993. eCollection 2022. Front Psychiatry. 2022. PMID: 36532193 Free PMC article. No abstract available.
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A; RAISE study group investigators. Kobayashi T, et al. Among authors: kato t. Lancet. 2012 Apr 28;379(9826):1613-20. doi: 10.1016/S0140-6736(11)61930-2. Epub 2012 Mar 8. Lancet. 2012. PMID: 22405251 Clinical Trial.
11,638 results
You have reached the last available page of results. Please see the User Guide for more information.